C
Cora N. Sternberg
Researcher at Cornell University
Publications - 747
Citations - 57991
Cora N. Sternberg is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 92, co-authored 663 publications receiving 48986 citations. Previous affiliations of Cora N. Sternberg include CTO Hospital & North Shore University Hospital.
Papers
More filters
Journal ArticleDOI
Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial.
Marcus R. Smith,Maha Hussain,Fred Saad,Karim Fizazi,Cora N. Sternberg,E. David Crawford,Evgeny Kopyltsov,Chandler H. Park,Boris Y. Alexeev,A. Montesa,Dingwei Ye,Francis Parnis,Felipe Melo Cruz,Teuvo T. L. Tammela,Hiroshi Suzuki,Heikki Joensuu,Silke Thiele,Rui-xia Li,Iris Kuss,Bertrand Tombal +19 more
TL;DR: The significant improvement in OS was observed even though substantially more pts received subsequent life-prolonging systemic antineoplastic therapy in the PBO arm (75.6%) vs the DARO arm (56.8%) and the significant OS benefit was consistent across prespecified subgroups.
Journal ArticleDOI
Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE-045.
Ronald de Wit,Dean F. Bajorin,Joaquim Bellmunt,Yves Fradet,Jae-Lyun Lee,Lawrence Fong,Nicholas J. Vogelzang,Miguel Angel Climent,Daniel P. Petrylak,Toni K. Choueiri,Andrea Necchi,Winald R. Gerritsen,Howard Gurney,David I. Quinn,Stéphane Culine,Cora N. Sternberg,Yabing Mai,Haojie Li,Rodolfo F. Perini,David J. Vaughn +19 more
TL;DR: Results of the prespecified HRQoL analysis of KEYNOTE-045 are presented, which shows pembro 200 mg Q3W significantly improved OS over investigator’s choice of paclitaxel, docetaxe, or vinflunine as second-line therapy for advanced UC following platinum-based chemo.
Journal ArticleDOI
Tivozanib in patients treatment-naive for metastatic renal cell carcinoma: A subset analysis of the phase III TIVO-1 study.
Cora N. Sternberg,Tim Eisen,Piotr Tomczak,Andrew Strahs,Brooke Esteves,Anna Berkenblit,Robert J. Motzer +6 more
TL;DR: Hypertension was more common with T, while lower rates of certain off-target AEs and fewer dose adjustments relative to S were reported, and safety analyses for the pre-specified subset of pts who received no prior systemic therapy for mRCC were presented.
Journal ArticleDOI
Pembrolizumab (pembro) plus epacadostat or placebo for locally advanced or metastatic urothelial carcinoma (UC) after failure of first-line platinum-containing chemotherapy: KEYNOTE-698/ECHO-303.
Thomas Powles,Joaquim Bellmunt,Daniel P. Petrylak,Lawrence Fong,Hiroyuki Nishiyama,Cora N. Sternberg,Mei Chen,Lei Pang,Mihaela Munteanu,Yufan Zhao,David Smith +10 more
TL;DR: Pembro has shown clinical efficacy as monotherapy in locally advanced or metastatic UC in first-line (1L) cis-ineligible and second- line (2L) postplatinum settings.
Journal ArticleDOI
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER.
Anthony M. Joshua,Andrew J. Armstrong,Megan Crumbaker,Howard I. Scher,Johann S. de Bono,Bertrand Tombal,Maha Hussain,Cora N. Sternberg,Silke Gillessen,Joan Carles,Karim Fizazi,Ping Lin,William T. Duggan,Jennifer Sugg,David W. Russell,Tomasz M. Beer +15 more
TL;DR: In this article , the association between statin or metformin use and rPFS, metastasis-free survival (MFS), toxicity and overall survival (OS) was investigated.